KR Choksey is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1591 in its ...

Aurobindo Pharma's net profit fell 10% to Rs 846 crore in Q3 FY25, while revenue rose to Rs 7,979 crore. The company attributes this to volume growth and new launches.

Report with market evolution powered by AI - The global antibiotics market size is estimated to grow by USD 18.22 billion ...

Pharma stocks tumbled as the Nifty Pharma index dropped two percent, with Alkem, Ipca, and Divi’s Labs leading losses.

Aurobindo Pharma reported a 10% YoY decline in net profit to Rs 846 crore for Q3FY25, mainly due to a decrease in US sales.

Ahead of earnings announcement, shares of Aurobindo Pharma ended the trading session flat at ₹1,184.50 apiece on the BSE, ...

Aurobindo Pharma on Thursday reported a 10 per cent year-on-year (Y-o-Y) drop in consolidated profit after tax (PAT) for the ...

The Hyderabad-based bulk and generic drug maker's net profit fell 9.7% year-on-year to Rs 846 crore in the quarter ended Dec.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Aurobindo Pharma's net profit declines 10% due to lower U.S. formulations revenue, but revenue from operations increases.